Cláudia Camila Dias1,2, Pedro Pereira Rodrigues1,2, Rosa Coelho3, Paula Moura Santos4, Samuel Fernandes4, Paula Lago5, Cidalina Caetano5, Ângela Rodrigues5, Francisco Portela6, Ana Oliveira6, Paula Ministro7, Eugénia Cancela7, Ana Isabel Vieira8, Rita Barosa8, José Cotter9, Pedro Carvalho10, Isabelle Cremers11, Daniel Trabulo11, Paulo Caldeira12,10, Artur Antunes10, Isadora Rosa13, Joana Moleiro13, Paula Peixe14, Rita Herculano14, Raquel Gonçalves15, Bruno Gonçalves15, Helena Tavares Sousa12,16, Luís Contente16, Henrique Morna17, Susana Lopes1, Fernando Magro1,18,19. 1. Health Information and Decision Sciences Department, Faculty of Medicine of the University of Porto, Porto, Portugal. 2. CINTESIS - Center for Health Technology and Services Research, Porto, Portugal. 3. Gastroenterology Department, Hospital São João, Porto, Portugal. 4. Gastroenterology Department, Faculty of Medicine, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisboa, Portugal. 5. Gastroenterology Department, Centro Hospitalar do Porto, Porto, Portugal. 6. Gastroenterology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. 7. Gastroenterology Department, Centro Hospitalar Tondela e Viseu, Tondela e Viseu, Portugal. 8. Gastroenterology Department, Hospital Garcia da Orta, Lisboa, Portugal. 9. Gastroenterology Department, Centro Hospitalar do Alto Ave, Guimarães, Portugal. 10. Gastroenterology Department, Hospital de Faro, Faro, Portugal. 11. Gastroenterology Department, Centro Hospitalar de Setúbal, Hospital São Bernardo, Setúbal, Portugal. 12. Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal. 13. Instituto Português de Oncologia Francisco Gentil, Lisboa, Portugal. 14. Gastroenterology Department, Centro Hospitalar Lisboa Oriental Portugal, Lisboa, Portugal. 15. Gastroenterology Department, Hospital de Braga, Braga, Portugal. 16. Gastroenterology Department, Portimão Unit, Centro Hospitalar do Algarve, Portimão, Portugal. 17. Gastroenterology Department, Hospital Nélio Mendonça, Funchal, Portugal. 18. Institute of Pharmacology and Therapeutics Faculty of Medicine of the University of Porto, Porto, Portugal. 19. MedInUP - Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal.
Abstract
INTRODUCTION: The establishment of prognostic models for Crohn's disease [CD] is highly desirable, as they have the potential to guide physicians in the decision-making process concerning therapeutic choices, thus improving patients' health and quality of life. Our aim was to derive models for disabling CD and reoperation based solely on clinical/demographic data. METHODS: A multicentric and retrospectively enrolled cohort of CD patients, subject to early surgery or immunosuppression, was analysed in order to build Bayesian network models and risk matrices. The final results were validated internally and with a multicentric and prospectively enrolled cohort. RESULTS: The derivation cohort included a total of 489 CD patients [64% with disabling disease and 18% who needed reoperation], while the validation cohort included 129 CD patients with similar outcome proportions. The Bayesian models achieved an area under the curve of 78% for disabling disease and 86% for reoperation. Age at diagnosis, perianal disease, disease aggressiveness and early therapeutic decisions were found to be significant factors, and were used to construct user-friendly matrices depicting the probability of each outcome in patients with various combinations of these factors. The matrices exhibit good performance for the most important criteria: disabling disease positive post-test odds = 8.00 [2.72-23.44] and reoperation negative post-test odds = 0.02 [0.00-0.11]. CONCLUSIONS: Clinical and demographical risk factors for disabling CD and reoperation were determined and their impact was quantified by means of risk matrices, which are applicable as bedside clinical tools that can help physicians during therapeutic decisions in early disease management.
INTRODUCTION: The establishment of prognostic models for Crohn's disease [CD] is highly desirable, as they have the potential to guide physicians in the decision-making process concerning therapeutic choices, thus improving patients' health and quality of life. Our aim was to derive models for disabling CD and reoperation based solely on clinical/demographic data. METHODS: A multicentric and retrospectively enrolled cohort of CD patients, subject to early surgery or immunosuppression, was analysed in order to build Bayesian network models and risk matrices. The final results were validated internally and with a multicentric and prospectively enrolled cohort. RESULTS: The derivation cohort included a total of 489 CD patients [64% with disabling disease and 18% who needed reoperation], while the validation cohort included 129 CD patients with similar outcome proportions. The Bayesian models achieved an area under the curve of 78% for disabling disease and 86% for reoperation. Age at diagnosis, perianal disease, disease aggressiveness and early therapeutic decisions were found to be significant factors, and were used to construct user-friendly matrices depicting the probability of each outcome in patients with various combinations of these factors. The matrices exhibit good performance for the most important criteria: disabling disease positive post-test odds = 8.00 [2.72-23.44] and reoperation negative post-test odds = 0.02 [0.00-0.11]. CONCLUSIONS: Clinical and demographical risk factors for disabling CD and reoperation were determined and their impact was quantified by means of risk matrices, which are applicable as bedside clinical tools that can help physicians during therapeutic decisions in early disease management.
Authors: Parambir S Dulai; Brigid S Boland; Siddharth Singh; Khadija Chaudrey; Jenna L Koliani-Pace; Gursimran Kochhar; Malav P Parikh; Eugenia Shmidt; Justin Hartke; Prianka Chilukuri; Joseph Meserve; Diana Whitehead; Robert Hirten; Adam C Winters; Leah G Katta; Farhad Peerani; Neeraj Narula; Keith Sultan; Arun Swaminath; Matthew Bohm; Dana Lukin; David Hudesman; John T Chang; Jesus Rivera-Nieves; Vipul Jairath; G Y Zou; Brian G Feagan; Bo Shen; Corey A Siegel; Edward V Loftus; Sunanda Kane; Bruce E Sands; Jean-Frederic Colombel; William J Sandborn; Karen Lasch; Charlie Cao Journal: Gastroenterology Date: 2018-05-30 Impact factor: 22.682
Authors: Cláudia Camila Dias; Pedro Pereira Rodrigues; Samuel Fernandes; Francisco Portela; Paula Ministro; Diana Martins; Paula Sousa; Paula Lago; Isadora Rosa; Luis Correia; Paula Moura Santos; Fernando Magro Journal: PLoS One Date: 2017-02-22 Impact factor: 3.240